Integer (NYSE:ITGR) Downgraded by Freedom Capital to “Hold”

Freedom Capital lowered shares of Integer (NYSE:ITGR) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

ITGR has been the subject of several other research reports. Piper Sandler downgraded shares of Integer from an “overweight” rating to a “hold” rating and set a $127.00 price target for the company. in a research report on Monday. HC Wainwright restated a “buy” rating on shares of Integer in a report on Friday, July 24th. Raymond James Financial lowered shares of Integer from a “moderate buy” rating to a “hold” rating in a research note on Monday. Citigroup lifted their price objective on shares of Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Finally, Truist Financial downgraded shares of Integer from a “buy” rating to a “hold” rating and boosted their target price for the stock from $110.00 to $127.00 in a research report on Monday. One analyst has rated the stock with a Buy rating and thirteen have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $109.86.

Integer Stock Performance

NYSE:ITGR opened at $124.94 on Tuesday. The company has a quick ratio of 2.38, a current ratio of 3.75 and a debt-to-equity ratio of 0.77. Integer has a twelve month low of $62.00 and a twelve month high of $125.54. The company has a fifty day moving average of $95.27 and a 200-day moving average of $89.56. The firm has a market capitalization of $4.24 billion, a P/E ratio of 31.16, a P/E/G ratio of 2.97 and a beta of 0.61.

Integer (NYSE:ITGR) last posted its quarterly earnings results on Monday, August 3rd. The medical equipment provider reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.38 by $0.22. The business had revenue of $464.11 million for the quarter, compared to the consensus estimate of $451.07 million. Integer had a return on equity of 12.77% and a net margin of 6.97%.The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.55 EPS. As a group, sell-side analysts anticipate that Integer will post 6.04 EPS for the current year.

Institutional Investors Weigh In On Integer

Several institutional investors have recently bought and sold shares of ITGR. Salomon & Ludwin LLC boosted its holdings in Integer by 46.8% during the 4th quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 118 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Integer by 48.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 117 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in shares of Integer by 1,037.5% in the fourth quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 415 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Integer by 135.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 267 shares during the last quarter. Finally, Arax Advisory Partners lifted its position in shares of Integer by 2,489.5% during the fourth quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 473 shares in the last quarter. Institutional investors own 99.29% of the company’s stock.

Integer News Roundup

Here are the key news stories impacting Integer this week:

• Positive Sentiment: KKR agreed to acquire Integer in an all-cash transaction valued at approximately $5.7 billion. Stockholders would receive $127 per share, representing a 51.8% premium to the price before Integer announced its strategic review and a 28.8% premium to the 30-day volume-weighted average price. The deal is expected to close by year-end 2026, subject to shareholder and regulatory approvals. Integer to Be Acquired by KKR
• Positive Sentiment: KKR’s backing is expected to give Integer additional capital and flexibility to invest in manufacturing capacity, technology, innovation and talent. The private-equity firm also plans an employee ownership program, potentially supporting retention and productivity. Integer Holdings KKR Deal
• Positive Sentiment: Integer’s second-quarter results exceeded expectations: adjusted earnings were $1.60 per share versus the $1.38 consensus estimate, while revenue of $464.1 million topped the $450.7 million estimate. Earnings also improved from $1.55 per share a year earlier. Integer Second Quarter 2026 Results
• Neutral Sentiment: Wells Fargo raised its price target from $84 to $127 but maintained an “equal weight” rating, leaving little implied upside beyond the proposed transaction price. Wells Fargo Price Target Update
• Negative Sentiment: Truist downgraded Integer from “strong buy” to “hold,” reflecting the stock’s proximity to the $127 offer and limited potential upside if the deal closes. Truist Downgrade
• Negative Sentiment: Revenue declined 2.6% year over year, and Integer withdrew its financial outlook and canceled its planned earnings call because of the pending acquisition. Several law firms are also investigating whether shareholders are receiving a fair price, creating potential deal-related uncertainty. Shareholder Investigation

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.